S.F.L. van Lelyveld

835 total citations
28 papers, 395 citations indexed

About

S.F.L. van Lelyveld is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, S.F.L. van Lelyveld has authored 28 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 13 papers in Virology and 8 papers in Epidemiology. Recurrent topics in S.F.L. van Lelyveld's work include HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (11 papers) and SARS-CoV-2 and COVID-19 Research (5 papers). S.F.L. van Lelyveld is often cited by papers focused on HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (11 papers) and SARS-CoV-2 and COVID-19 Research (5 papers). S.F.L. van Lelyveld collaborates with scholars based in Netherlands, Germany and United States. S.F.L. van Lelyveld's co-authors include Andy I. M. Hoepelman, Annemarie M. J. Wensing, Luuk Gras, Frank de Wolf, Monique Nijhuis, Anouk M Kesselring, Shuangjie Zhang, Kiki Tesselaar, A. I. M. Hoepelman and Petra M. van Ham and has published in prestigious journals such as PLoS ONE, Neurology and Clinical Infectious Diseases.

In The Last Decade

S.F.L. van Lelyveld

27 papers receiving 391 citations

Peers

Countries citing papers authored by S.F.L. van Lelyveld

Since Specialization

Citations

This map shows the geographic impact of S.F.L. van Lelyveld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.F.L. van Lelyveld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.F.L. van Lelyveld more than expected).

Fields of papers citing papers by S.F.L. van Lelyveld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.F.L. van Lelyveld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.F.L. van Lelyveld. The network helps show where S.F.L. van Lelyveld may publish in the future.

Co-authorship network of co-authors of S.F.L. van Lelyveld

This figure shows the co-authorship network connecting the top 25 collaborators of S.F.L. van Lelyveld. A scholar is included among the top collaborators of S.F.L. van Lelyveld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.F.L. van Lelyveld. S.F.L. van Lelyveld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen 2024 ·Viruses ·(unknown), (unknown), Wouter F.W. Bierman, Reinout van Crevel, Andy I. M. Hoepelman, Mark A. A. Claassen, Heidi Ammerlaan, Berend J. van Welzen, M.E.E. van Kasteren, S.F.L. van Lelyveld, Dorien de Jong, Kiki Tesselaar, Matthijs van Luin, Monique Nijhuis, Annemarie M. J. Wensing, (unknown)	2
2	The role of antibody-dependent enhancement in dengue vaccination 2024 ·Tropical Diseases Travel Medicine and Vaccines ·(unknown), (unknown), Leanne P. M. van Leeuwen, Thomas Langerak, M Hakim, B Martina, S.F.L. van Lelyveld, Eric C. M. Van Gorp	14
3	Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC) 2024 ·Biomedicines ·(unknown), (unknown), S.F.L. van Lelyveld, B Martina, Colin A. Russell, Marco Goeijenbier	1
4	Lower Levels of Household Transmission of SARS-CoV-2 Omicron Variant of Concern vs Wild Type: An Interplay Between Transmissibility and Immune Status 2024 ·The Journal of Infectious Diseases ·(unknown), (unknown), (unknown), Sjoerd M. Euser, (unknown), Rob Mariman, (unknown), (unknown), (unknown), Marlies A. van Houten, Dirk Eggink, S.F.L. van Lelyveld	2
5	Post COVID-19 Pandemic Increased Detection of Mycoplasma Pneumoniae in Adults Admitted to the Intensive Care 2024 ·Journal of Clinical Medicine ·Marco Goeijenbier, (unknown), Dennis Souverein, (unknown), Michael Nagel, Susanne P. Stoof, (unknown), Jan-Willem Weenink, Eric C. M. Van Gorp, Sjoerd M. Euser, Jayant Kalpoe, Marlies A. van Houten, Henrik Endeman, Diederik Gommers, Lenneke Haas, S.F.L. van Lelyveld	2
6	A Systematic Review of the Pulmonary Microbiome in Patients with Acute Exacerbation COPD Requiring ICU Admission 2024 ·Journal of Clinical Medicine ·(unknown), Mark E. Haaksma, (unknown), (unknown), Eric C. M. Van Gorp, Thomas Langerak, Henrik Endeman, Dominic Snijders, Johannes P. C. van den Akker, Marlies A. van Houten, S.F.L. van Lelyveld, Marco Goeijenbier	1
7	Long term sequelae after SARS-CoV-2 infection in children: a household study 2023 ·Virology Journal ·(unknown), (unknown), Joanne Wildenbeest, S.F.L. van Lelyveld, Patricia Bruijning‐Verhagen, (unknown)	0
8	High Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission Rates Detected by Dense Saliva Sampling 2022 ·Clinical Infectious Diseases ·(unknown), S.F.L. van Lelyveld, (unknown), Rob Mariman, (unknown), (unknown), Emma M. de Koff, (unknown), Willem R. Miellet, (unknown), Claudia E. Coipan, Adam Meijer, Elisabeth A. M. Sanders, Krzysztof Trzciński, Sjoerd M. Euser, Dirk Eggink, (unknown)	13
9	The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients 2018 ·HIV Clinical Trials ·(unknown), Kiki Tesselaar, Guido E.L. van den Berk, Sigrid A. Otto, (unknown), S.F.L. van Lelyveld, Frank L.J. Visseren, Andy I. M. Hoepelman, Joop E. Arends	7
10	Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study 2016 ·Infectious Diseases and Therapy ·(unknown), Kiki Tesselaar, Joop E. Arends, Julia Drylewicz, Sigrid A. Otto, S.F.L. van Lelyveld, Frank L.J. Visseren, Andy I. M. Hoepelman	5
11	Diminished Impact of Ethnicity as a Risk Factor for Chronic Kidney Disease in the Current HIV Treatment Era 2015 ·The Journal of Infectious Diseases ·Annelot F. Schoffelen, Colette Smit, S.F.L. van Lelyveld, Liffert Vogt, (unknown), Peter Reiss, Andy I. M. Hoepelman, Roos E. Barth	6
12	Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients 2015 ·International Journal of Antimicrobial Agents ·S.F.L. van Lelyveld, Jori Symons, (unknown), Bridgette J. Connell, Monique Nijhuis, Annemarie M. J. Wensing, A. I. M. Hoepelman	2
13	Quantification of naive and memory T-cell turnover during HIV-1 infection 2015 ·AIDS ·Nienke Vrisekoop, Julia Drylewicz, Rogier van Gent, Tendai Mugwagwa, S.F.L. van Lelyveld, (unknown), Sigrid A. Otto, Mariëtte T. Ackermans, (unknown), Hidde H. Huidekoper, Jan M. Prins, Frank Miedema, Rob J. de Boer, Kiki Tesselaar, José A. M. Borghans	22
14	Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial 2015 ·PLoS ONE ·S.F.L. van Lelyveld, Julia Drylewicz, (unknown), (unknown), Sigrid A. Otto, Clemens Richter, Robin Soetekouw, Jan M. Prins, Kees Brinkman, Jan W. Mulder, Frank P. Kroon, (unknown), Jori Symons, Annemarie M. J. Wensing, Monique Nijhuis, José A. M. Borghans, Kiki Tesselaar, Andy I. M. Hoepelman, (unknown)	26
15	Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands host or environmental factors? 2013 ·AIDS ·Annelot F. Schoffelen, S.F.L. van Lelyveld, Roos E. Barth, Luuk Gras, Frank de Wolf, Mihai G. Netea, Andy I. M. Hoepelman	12
16	Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint 2013 ·Journal of Antimicrobial Chemotherapy ·(unknown), Jori Symons, Art F. Y. Poon, P. Richard Harrigan, S.F.L. van Lelyveld, Andy I. M. Hoepelman, Petra M. van Ham, Winnie Dong, Annemarie M. J. Wensing, Monique Nijhuis	8
17	Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice 2011 ·Clinical Microbiology and Infection ·Jori Symons, Linos Vandekerckhove, Roger Paredes, Chris Verhofstede, (unknown), Els Demecheleer, Petra M. van Ham, S.F.L. van Lelyveld, (unknown), (unknown), Monique Nijhuis, Annemarie M. J. Wensing	22
18	Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort 2011 ·AIDS ·S.F.L. van Lelyveld, Luuk Gras, Anouk M Kesselring, Shuangjie Zhang, Frank de Wolf, Annemarie M. J. Wensing, Andy I. M. Hoepelman	85
19	Therapy Failure following Selection of Enfuvirtide‐Resistant HIV‐1 in Cerebrospinal Fluid 2010 ·Clinical Infectious Diseases ·S.F.L. van Lelyveld, Monique Nijhuis, (unknown), Ingeborg Wilting, Walter M. van den Bergh, Michael Kurowski, (unknown), A. I. M. Hoepelman, Amj Wensing	26
20	Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity 2010 ·Journal of Antimicrobial Chemotherapy ·Axel Fun, Karen Van Baelen, S.F.L. van Lelyveld, P Schipper, Lieven Stuyver, Annemarie M. J. Wensing, Monique Nijhuis	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact